Adherence to disease-modifying therapies and attitudes regarding disease in patients with multiple sclerosis

被引:9
|
作者
Ozura, Ana [1 ]
Kovac, Lea [2 ]
Sega, Sasa [1 ]
机构
[1] Univ Med Ctr Ljubljana, Div Neurol, Ljubljana 1000, Slovenia
[2] Univ Ljubljana, Fac Med, Ljubljana 1104, Slovenia
关键词
Multiple sclerosis; Patient adherence; Disease-modifying treatment; Side effects; Attitudes; MEDICATION ADHERENCE; PERSISTENCE; TOLERABILITY; ASSOCIATION; MULTICENTER; IMPACT; DRUGS;
D O I
10.1016/j.clineuro.2013.09.013
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Although currently there is no cure for MS the course of the disease can be influenced by disease modifying therapy (DMT). For therapy to be sufficiently efficient, it is crucial that patients take their medication regularly as prescribed. Adherence describes the extent to which a patient acts in accordance with the prescribed timing, dosing, and frequency of medication administration. To date, there are no known data about adherence rates among patients with MS in Slovenia. We wanted to assess adherence in patients with MS, who are treated with first line DMTs and discover reasons for non-adherence. A number of 451 patients were invited to participate. They received two questionnaires via post mail. The adherence rate and putative reasons for non-adherence were assessed by the use of standardized self-report Multiple Sclerosis Treatment Experience Questionnaire (MSTEQ). Patients' attitudes regarding disease, therapy and relationship with their physician were assessed by another questionnaire. The analysis of results included 299 patients. Among the patients 18.5% missed at least one medication dose in the past 28 days. Patients taking Avonex were significantly more adherent then patients on other DMTs (p = 0.005). Our study showed a higher then expected adherence among Slovenian patients with MS (81.5%). Our research did not confirm the influence of side effects or patients' attitudes regarding illness and therapy on adherence. However we found unexpectedly high percentage (71.8%) of patients belief that psychological factors are involved in MS aetiology. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:S6 / S11
页数:6
相关论文
共 50 条
  • [1] Adherence to disease-modifying therapies in patients with multiple sclerosis
    Koltuniuk, Aleksandra
    Rosinczuk, Joanna
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2018, 12 : 1557 - 1565
  • [2] Adherence to Disease-Modifying Therapies for Multiple Sclerosis
    Higuera, Lucas
    Carlin, Caroline S.
    Anderson, Sarah
    [J]. Journal of Managed Care & Specialty Pharmacy, 2016, 22 (12): : 1394 - 1401
  • [3] Fostering adherence to injectable disease-modifying therapies in multiple sclerosis
    Lugaresi, Alessandra
    Rottoli, Maria Rosa
    Patti, Francesco
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (09) : 1029 - 1042
  • [4] Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
    Zanga, Gisela
    Drzewiscki, Estefania
    Tagliani, Paula
    Smietniansky, Maximiliano
    Rojas, Maria M. Esnaola y
    Caruso, Diego
    [J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [5] Adherence to Multiple Sclerosis Disease-Modifying Therapies in Ontario is Low
    Wong, Janice
    Gomes, Tara
    Mamdani, Muhammad
    Manno, Michael
    O'Connor, Paul W.
    [J]. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2011, 38 (03) : 429 - 433
  • [6] Adherence to Multiple Sclerosis Disease-Modifying Therapies in Ontario Is Low
    Wong, Janice
    Gomes, Tara
    Mamdani, Muhammad
    Manno, Michael
    O'Connor, Paul W.
    [J]. NEUROLOGY, 2011, 76 (09) : A465 - A465
  • [7] Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations
    Evans, Charity
    Marrie, Ruth Ann
    Zhu, Feng
    Leung, Stella
    Lu, Xinya
    Kingwell, Elaine
    Zhao, Yinshan
    Tremlett, Helen
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (06) : 702 - 711
  • [8] Association between multiple sclerosis disease severity and adherence to disease-modifying therapies
    Burkhard, Adam
    Toliver, Joshua
    Rascati, Karen
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (07): : 915 - 923
  • [9] Multiple sclerosis and disease-modifying therapies
    Minen, Mia T.
    Karceski, Steven
    [J]. NEUROLOGY, 2011, 77 (04) : E26 - E26
  • [10] Disease-modifying therapies for multiple sclerosis
    De Angelis, Floriana
    John, Nevin A.
    Brownlee, Wallace J.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2018, 363